Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharm Technol ; 39(3): 123-133, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37323768

ABSTRACT

Background: Two common dosing strategies for vancomycin are trough-based and area under the curve (AUC)-based dosing. Objective: To compare the incidence of nephrotoxicity in trough-based dosing group with the single trough-based AUC dosing at the Salem VA Medical Center. Methods: This retrospective study included patients who received trough-based dosing of vancomycin between January 1, 2017, and January 1, 2019 (preimplementation group) and AUC-based dosing (postimplementation) between October 1, 2019, and October 1, 2021, at the Salem VA Medical Center. The primary outcome was nephrotoxicity at 96 hours, 7 days, and entire hospital length of stay (LOS). Secondary outcomes included 30-day readmission and all-cause mortality rates, cumulative doses at 24, 48, and 72 hours, and percentage of patients considered at goal (AUC 400-600 or trough between 10 and 20 mg/L). Propensity score (PS) matching was utilized to adjust for confounding. Results: After PS matching 100 patients were included in preimplementation and 95 patients in the postimplementation group. The average study patient was a 68-year-old white male. There was significant reduction in the risk of nephrotoxicity in postimplementation cohort at 96 hours (adjusted (a)HR: 0.28, 95% CI (0.12-0.66); 7 days (aHR: 0.39, 95% CI (0.18-0.85); and entire hospital LOS (aHR: 0.46, 95% CI (0.22-0.95). Secondary outcomes showed no difference between the groups except significantly higher proportion of patients were considered at therapeutic goal in the postimplementation cohort compared with pre-implementation cohort. Conclusion: This hypothesis generating study shows that AUC-based dosing calculated using single trough concentration may result in reduced rate of nephrotoxicity than trough-based dosing.

2.
Infect Dis Clin North Am ; 37(1): 153-173, 2023 03.
Article in English | MEDLINE | ID: mdl-36805011

ABSTRACT

Effective and consistent antiretroviral therapy has enabled people with human immunodeficiency virus (HIV) (PWH) to survive longer than previously encountered earlier in the epidemic. Consequently, PWH are subject to the struggles and clinical conditions typically associated with aging. However, the aging process in PWH is not the same as for those who do not have HIV. There is a complex interplay of molecular, microbiologic, and pharmacologic factors that leads to accelerated aging in PWH; this leads to increased risk for certain age-related comorbidities requiring greater vigilance and interventions in routine care.


Subject(s)
HIV Infections , HIV , Humans , Aging , HIV Infections/complications , HIV Infections/drug therapy , HIV Infections/epidemiology , Comorbidity
3.
Am J Med Sci ; 364(1): 88-91, 2022 07.
Article in English | MEDLINE | ID: mdl-35172188

ABSTRACT

Nocardia is an uncommon cause of septic arthritis. We found only 37 cases reported in the literature thus far. Amongst these, only five involved prosthetic joints. Three cases were caused by N. nova and one each by N. farcinica and asteroides. Septic arthritis due to Nocardia has a favorable outcome with a combination of surgical debridement and prolonged antimicrobial therapy of three to six months. For prosthetic joint infections, removal of hardware seems to carry a better prognosis. Trimethoprim-sulfamethoxazole continues to remain the drug of choice.


Subject(s)
Arthritis, Infectious , Nocardia Infections , Nocardia , Anti-Bacterial Agents/therapeutic use , Arthritis, Infectious/diagnosis , Arthritis, Infectious/drug therapy , Humans , Nocardia Infections/diagnosis , Nocardia Infections/drug therapy , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
4.
Nurs Adm Q ; 42(4): 363-372, 2018.
Article in English | MEDLINE | ID: mdl-30180083

ABSTRACT

Implementation and dissemination of an oral care initiative enhanced the safety and well-being of Veterans at the Salem VA Medical Center by reducing the risk of non-ventilator-associated hospital-acquired pneumonia (NV-HAP). The incidence rate of non-ventilator-associated hospital-acquired pneumonia decreased from 105 cases to 8.3 cases per 1000 patient-days (by 92%) in the initial VA pilot, yielding an estimated cost avoidance of $2.84 million and 13 lives saved in 19 months postimplementation. The team was successful in translating this research into a meaningful quality improvement intervention in 8 VA hospitals (in North Carolina, Texas, and Virginia) that has promoted effective and consistent delivery of oral care across hospital service lines and systems, improved the health of Veterans, and driven down health care costs associated with this largely preventable illness. The steps needed for successful replication and dissemination of this nurse-led, evidence-based practice are summarized in this article.


Subject(s)
Dental Care/methods , Pneumonia/prevention & control , Teaching/standards , Airway Management/adverse effects , Airway Management/methods , Dental Care/standards , Humans , Iatrogenic Disease/prevention & control , Toothbrushing/methods , United States , United States Department of Veterans Affairs/organization & administration , United States Department of Veterans Affairs/statistics & numerical data , Veterans/statistics & numerical data
5.
Compr Ther ; 31(1): 59-71, 2005.
Article in English | MEDLINE | ID: mdl-15793325

ABSTRACT

Disorders of flushing encompass a broad spectrum of diverse acquired and inherited conditions. Chemical mediators involved in the flushing response are incompletely understood. Flushing episodes rarely can be associated with significant morbidity and mortality. The goal of the physician is to separate benign from potentially life-threatening conditions. Accurate diagnosis requires a thorough history and physical examination emphasizing the age of the patient, temporal association of flushing with occupation, environmental, stress, food, or drug exposure, and the duration of the episode. In some cases, despite a thorough evaluation, the etiology for flushing remains unknown. Understanding the distinct mechanisms that lead to flushing helps provide a rational approach to treatment.


Subject(s)
Flushing/diagnosis , Flushing/etiology , Alcohol Drinking/adverse effects , Autonomic Nervous System Diseases/complications , Diagnosis, Differential , Drug-Related Side Effects and Adverse Reactions , Humans , Marine Toxins/poisoning , Neoplasms/complications , Occupational Exposure/adverse effects , Postmenopause , Rosacea/complications , Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL
...